• Fosun Pharma Industrial won clearance in China for a Phase II/III adaptive seamless trial of FXS5626 in non-segmental vitiligo.
• Trial start planned in mainland China once conditions are met.
• FXS5626 is an oral TYK2/JAK1 dual-target JAK inhibitor licensed for development, manufacturing, registration, commercialization in mainland China, Hong Kong, Macau.
• Group R&D spending on FXS5626 reached about RMB 108 million as of August 2026, including license fees.
• No TYK2/JAK1 dual-target inhibitor has been cleared for launch in mainland China as of Sept. 8, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Fosun Pharmaceutical (Group) Co. Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260908-12324642), on September 08, 2026, and is solely responsible for the information contained therein.